Form 4: Regulus Therapeutics Director Disposes All Holdings Following Novartis Acquisition

David Baltimore, a Director of Regulus Therapeutics Inc., has disposed of all his direct and indirect beneficial ownership in the company following its acquisition by Novartis AG for $7.00 cash per share plus a contingent value right.

Summary

• Regulus Therapeutics Inc. (RGLS) has been acquired by Novartis AG through its wholly-owned, indirect subsidiary, Redwood Merger Sub Inc.
• The merger became effective on June 25, 2025, with Regulus Therapeutics Inc. continuing as the surviving corporation and a wholly-owned subsidiary of Novartis AG.
• Shareholders of Regulus Therapeutics Inc. received an 'Offer Price' consisting of (a) $7.00 in cash per common share (the 'Closing Amount') and (b) one Contingent Value Right (CVR) per share.
• Each CVR represents the right to receive an additional contingent payment of $7.00 in cash upon the achievement of a specified milestone.
• Director David Baltimore disposed of all his directly and indirectly held common stock and stock options as a result of this merger.
• His direct beneficial ownership of common stock, totaling 84,669 shares (27,377 + 57,292), was disposed of.
• His indirect beneficial ownership of common stock (by spouse), totaling 62,500 shares (5,208 + 57,292), was also disposed of.
• In-the-money stock options (exercise price less than $7.00) were canceled and converted into a cash payment (Closing Amount minus exercise price) plus one CVR per underlying share.
• Out-of-the-money stock options (exercise price equal to or greater than $7.00 but less than $14.00) were canceled and converted into one CVR per underlying share, with a potential cash payment if the CVR milestone is met.

Sentiment

Score: 7

Explanation: The sentiment is positive as the merger has successfully completed, providing liquidity to shareholders at a defined cash price with potential upside from a CVR. While the CVR introduces contingency, the overall event is a successful acquisition for the company and its shareholders.

Positives

• The acquisition provides immediate liquidity to Regulus Therapeutics Inc. shareholders with a cash payment of $7.00 per share.
• Shareholders received Contingent Value Rights (CVRs) which offer potential for an additional $7.00 per share, providing a contingent upside to the transaction.
• The merger provides Regulus Therapeutics Inc. with the resources and backing of a major pharmaceutical company, Novartis AG.

Negatives

• Regulus Therapeutics Inc. is no longer an independent publicly traded company, which may limit future direct investment opportunities in the entity.
• The full potential value of $14.00 per share is contingent on the achievement of a specific milestone, introducing uncertainty regarding the CVR payment.

Risks

• The contingent payment of $7.00 per CVR is entirely dependent on the achievement of a specific milestone, which may not occur, meaning shareholders might only receive the initial $7.00 cash payment.
• The terms and conditions governing the CVRs, including the specific milestone, are not fully detailed in this Form 4 filing, creating potential for misinterpretation or unforeseen issues.

Future Outlook

Regulus Therapeutics Inc. will now operate as a wholly-owned subsidiary of Novartis AG, integrating its operations and strategic direction within the larger parent company. The future financial performance and strategic focus of Regulus will be determined by Novartis. The contingent value rights (CVRs) offer a potential future payment of $7.00 per share, contingent upon the achievement of a specific milestone, providing a potential future cash flow event for former shareholders.

Industry Context

This acquisition reflects a continuing trend of consolidation within the biotechnology and pharmaceutical industries, where larger companies like Novartis seek to expand their pipelines and intellectual property through strategic acquisitions of smaller, innovative biotech firms. Such mergers can provide the acquired company with significant financial resources and development capabilities, while offering the acquirer access to novel therapeutic candidates or platforms.

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, providing a return on investment and potential future upside.
• Employees: Will be integrated into Novartis AG's organizational structure, which may involve changes in roles, reporting lines, and benefits.
• Company (Regulus Therapeutics Inc.): Transitions from an independent public entity to a wholly-owned subsidiary, gaining access to Novartis's resources and global reach.

Next Steps

• Former shareholders of Regulus Therapeutics Inc. will receive the initial cash payment and the Contingent Value Rights (CVRs) as per the merger agreement.
• Holders of CVRs will await the achievement of the specified milestone to potentially receive the contingent cash payment.
• Regulus Therapeutics Inc. will continue its operations as a wholly-owned subsidiary, integrating into Novartis AG's corporate structure.

Key Dates

Keywords

Regulus Therapeutics, Novartis AG, Merger, Acquisition, SEC Form 4, Beneficial Ownership, Contingent Value Right, CVR, Stock Options, Common Stock, Insider Transaction, David Baltimore, RGLS